167 related articles for article (PubMed ID: 35961800)
1. The mythological chimera and new era of relapse prediction post-transplant.
Ciurea SO; Kothari A; Sana S; Al Malki MM
Blood Rev; 2023 Jan; 57():100997. PubMed ID: 35961800
[TBL] [Abstract][Full Text] [Related]
2. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
3. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
4. Chimerism Testing by Next Generation Sequencing for Detection of Engraftment and Early Disease Relapse in Allogeneic Hematopoietic Cell Transplantation and an Overview of NGS Chimerism Studies.
Liacini A; Tripathi G; McCollick A; Gravante C; Abdelmessieh P; Shestovska Y; Mathew L; Geier S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511573
[TBL] [Abstract][Full Text] [Related]
5. Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.
Pincez T; Santiago R; Bittencourt H; Louis I; Bilodeau M; Rouette A; Jouan L; Landry JR; Couture F; Richer J; Teira P; Duval M; Cellot S
Bone Marrow Transplant; 2021 Dec; 56(12):2981-2989. PubMed ID: 34475524
[TBL] [Abstract][Full Text] [Related]
6. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Bacher U; Haferlach T; Fehse B; Schnittger S; Kröger N
ScientificWorldJournal; 2011 Feb; 11():310-9. PubMed ID: 21298222
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
9. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.
Wong ZC; Dillon LW; Hourigan CS
Best Pract Res Clin Haematol; 2023 Jun; 36(2):101468. PubMed ID: 37353292
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
11. Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation: Comparison of Two Chimerism Test Strategies, Next-Generation Sequencing versus a Combination of Short-Tandem Repeats and Quantitative PCR.
Zhang A; Macecevic S; Thomas D; Allen J; Mandley S; Kawczak P; Jurcago R; Tyler J; Casey H; Bosler D; Sobecks R; Hamilton B; Sauter C; Mineishi S; Claxton D; Shike H
J Mol Diagn; 2024 Apr; 26(4):233-244. PubMed ID: 38307253
[TBL] [Abstract][Full Text] [Related]
12. Highly sensitive chimerism detection in blood is associated with increased risk of relapse after allogeneic hematopoietic cell transplantation in childhood leukemia.
Haugaard AK; Madsen HO; Marquart HV; Rosthøj S; Masmas TN; Heilmann C; Müller KG; Ifversen M
Pediatr Transplant; 2019 Nov; 23(7):e13549. PubMed ID: 31313439
[TBL] [Abstract][Full Text] [Related]
13. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.
Kanaan SB; Urselli F; Radich JP; Nelson JL
Blood Adv; 2023 Oct; 7(20):6066-6079. PubMed ID: 37467017
[TBL] [Abstract][Full Text] [Related]
15. Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Smallbone P; Louw A; Purtill D
Pathology; 2024 Feb; 56(1):24-32. PubMed ID: 38071159
[TBL] [Abstract][Full Text] [Related]
16. [Dynamic detection of chimerism and fusion gene in chronic myeloid leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation].
Sun JF; Zhao DD; Han XP; Jin HS; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):833-7. PubMed ID: 18718071
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
18. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
19. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
[TBL] [Abstract][Full Text] [Related]
20. Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation.
Elmaagacli AH
Int J Hematol; 2002 Aug; 76 Suppl 2():204-5. PubMed ID: 12430926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
